Welcome to our dedicated page for Keros Therapeutics news (Ticker: KROS), a resource for investors and traders seeking the latest updates and insights on Keros Therapeutics stock.
Keros Therapeutics, Inc. (Nasdaq: KROS) is a clinical-stage biopharmaceutical company whose news flow centers on its TGF-ß pathway–focused pipeline, corporate strategy and capital allocation decisions. The company’s disclosures describe a focus on developing protein therapeutics for disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins, with particular emphasis on neuromuscular and hematologic conditions.
News about Keros frequently highlights clinical development milestones for its lead product candidate, KER-065, which is being developed for neuromuscular diseases with an initial focus on Duchenne muscular dystrophy. Recent updates have included Phase 1 clinical data in healthy volunteers, additional analyses of bone and muscle-related endpoints, and U.S. Food and Drug Administration Orphan Drug designation for KER-065 in DMD. Investors following KROS news can expect coverage of trial design, safety and pharmacodynamic findings, and plans for subsequent clinical phases.
Another recurring theme in Keros news is progress related to elritercept, the company’s most advanced product candidate for cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and myelofibrosis. The company has reported developments under its global license agreement with Takeda Pharmaceuticals U.S.A., Inc., including Takeda’s plans to advance elritercept into a Phase 3 clinical trial in first-line myelodysplastic syndromes.
Keros’ news flow also includes corporate and financial updates. These have covered a strategic realignment to prioritize KER-065, discontinuation of internal development of cibotercept (KER-012), leadership and board changes, and a substantial capital return program involving stock repurchase agreements and a cash tender offer for a significant portion of its outstanding common stock. Earnings releases and Form 8-K filings provide additional context on financial results, cash position and the execution of the capital return plan.
For investors and observers, the KROS news page offers a consolidated view of clinical trial announcements, regulatory designations, partnership developments, governance changes and capital allocation actions that shape the company’s trajectory. Regular review of these updates can help track how Keros advances its TGF-ß–focused pipeline and manages its resources over time.
Keros Therapeutics (NASDAQ: KROS) reported its Q3 2024 financial results and business highlights. The company announced completion of enrollment ahead of schedule in Phase 2 TROPOS trial of cibotercept. Financial results showed a net loss of $53.0 million compared to $39.4 million in Q3 2023. R&D expenses increased to $49.2 million from $34.1 million year-over-year. The company's cash position strengthened to $530.7 million, expected to fund operations into Q3 2027. Keros also appointed Yung H. Chyung as Chief Medical Officer effective November 1, 2024.
Keros Therapeutics (Nasdaq: KROS), a clinical-stage biopharmaceutical company specializing in TGF-ß signaling disorders, has announced its upcoming participation in the Guggenheim Healthcare Innovation Conference. Chair and CEO Jasbir S. Seehra, Ph.D., will engage in a fireside chat presentation on November 13, 2024, at 3:30 p.m. Eastern time.
The presentation will be accessible via live audio webcast, with an archived version available on the company's investor relations website for 90 days after the event.
Keros Therapeutics (Nasdaq: KROS) has announced the presentation of three abstracts from its hematology program at the 66th American Society of Hematology (ASH) Annual Meeting from December 7-10, 2024. The presentations will showcase additional results from two ongoing Phase 2 clinical trials of elritercept (KER-050).
The trials focus on patients with lower-risk myelodysplastic syndrome (MDS) and myelofibrosis (MF). The presentations will highlight improvements in hematological parameters, quality of life, and clinical benefits of elritercept both as monotherapy and in combination with ruxolitinib. The abstracts were made public on the ASH website on November 5, 2024.
Keros Therapeutics (Nasdaq: KROS), a clinical-stage biopharmaceutical company, has announced an updated time for its presentation at the 2024 Cantor Global Healthcare Conference. The company's Chair and CEO, Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation on Thursday, September 19, 2024, at 8:00 a.m. Eastern time.
Keros focuses on developing novel therapeutics for disorders linked to dysfunctional signaling of the transforming growth factor-beta (TGF-ß) family of proteins. The presentation will be available via live audio webcast, with an archived replay accessible on the company's investor relations website for up to 90 days after the event.
Keros Therapeutics (Nasdaq: KROS) has announced the closure of screening for its TROPOS trial, a Phase 2 clinical study of cibotercept (KER-012) in combination with background therapy for patients with pulmonary arterial hypertension (PAH). The company expects to complete enrollment by the end of September and present topline data in Q2 2025, earlier than initially anticipated due to high demand and rapid enrollment. Keros, focused on developing therapies for disorders linked to dysfunctional TGF-ß family protein signaling, aims to bring a potentially differentiated treatment option to PAH patients. The company's leadership expressed gratitude to the investigators, research staff, and patients involved in this significant clinical research milestone.
Keros Therapeutics (Nasdaq: KROS), a clinical-stage biopharmaceutical company, has announced its participation in three upcoming healthcare conferences in September 2024. The company's Chair and CEO, Jasbir S. Seehra, Ph.D., will present at:
1. Morgan Stanley 22nd Annual Global Healthcare Conference on September 4 at 4:05 p.m. ET
2. 2024 Wells Fargo Healthcare Conference on September 5 at 10:15 a.m. ET
3. 2024 Cantor Global Healthcare Conference on September 19 at 8:35 a.m. ET
All presentations will be in a fireside chat format. Archived replays will be available on the Keros website for up to 90 days after each event. Keros focuses on developing therapeutics for disorders linked to dysfunctional signaling of the TGF-ß family of proteins.
Keros Therapeutics (Nasdaq: KROS) reported its Q2 2024 financial results, showing a net loss of $45.3 million, up from $37.5 million in Q2 2023. The increase was primarily due to expanded R&D efforts and investments in clinical and corporate goals. Research and development expenses rose to $40.5 million from $32.5 million year-over-year, while general and administrative expenses increased to $10.0 million from $8.8 million. Despite the losses, Keros' cash position strengthened to $405.9 million as of June 30, 2024, up from $331.1 million at the end of 2023. The company expects this cash reserve to fund operations into 2027. Keros highlighted positive regulatory and data updates for its elritercept (KER-050) program and strong enrollment in the Phase 2 trial of cibotercept (KER-012) for pulmonary arterial hypertension.
Keros Therapeutics (Nasdaq: KROS) announced leadership changes effective July 1, 2024. Dr. Jasbir Seehra, currently CEO, will become Chair of the Board, succeeding Dr. Carl Gordon, who will remain an active Board member. Jean-Jacques Bienaimé will take over as Lead Independent Director of the Board. Additionally, Christopher Rovaldi has been promoted to President, while retaining his role as Chief Operating Officer. These changes come as Keros prepares for its first Phase 3 clinical trial of elritercept (KER-050) for lower-risk myelodysplastic syndromes. Dr. Seehra and Dr. Gordon both expressed confidence in the new leadership structure to drive the company's strategic and operational priorities.
Keros Therapeutics presented new clinical data from its ongoing Phase 2 trials of elritercept (KER-050) at the 29th Annual Hybrid Congress of the European Hematology Association. The data highlights elritercept's potential in treating lower-risk myelodysplastic syndromes (MDS) and myelofibrosis (MF). Key findings include durable transfusion independence, improved patient fatigue scores, and reductions in spleen volume. Elritercept was generally well-tolerated with no treatment-related fatalities. Keros plans to initiate a Phase 3 clinical trial in MDS following positive FDA feedback, marking a significant step towards potential commercialization.
Keros Therapeutics (Nasdaq: KROS) announced a corporate update conference call and webcast on June 17, 2024, at 8:00 a.m. Eastern time. The company received positive feedback from the FDA regarding its KER-050 (elritercept) program for myelodysplastic syndromes (MDS), aligning on the design and endpoints for the proposed Phase 3 clinical trial. CEO Jasbir S. Seehra, Ph.D., mentioned ongoing Phase 2 TROPOS trial for KER-012 (cibotercept) in pulmonary arterial hypertension (PAH), with enrollment expected to complete in Q4 this year. The webcast will be accessible via Keros’s website, with an archived version available for 90 days post-call.